Pfizer Inc. (NYSE:PFE) Shares Sold by ORG Wealth Partners LLC

ORG Wealth Partners LLC lessened its stake in Pfizer Inc. (NYSE:PFE) by 46.6% during the fourth quarter, HoldingsChannel.com reports. The firm owned 2,114 shares of the biopharmaceutical company’s stock after selling 1,847 shares during the period. ORG Wealth Partners LLC’s holdings in Pfizer were worth $56,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Hilltop National Bank raised its stake in Pfizer by 8.2% during the fourth quarter. Hilltop National Bank now owns 19,077 shares of the biopharmaceutical company’s stock worth $506,000 after acquiring an additional 1,450 shares during the period. A. D. Beadell Investment Counsel Inc. raised its stake in Pfizer by 7.7% during the fourth quarter. A. D. Beadell Investment Counsel Inc. now owns 47,211 shares of the biopharmaceutical company’s stock worth $1,252,000 after acquiring an additional 3,375 shares during the period. ST Germain D J Co. Inc. raised its stake in Pfizer by 17.5% during the fourth quarter. ST Germain D J Co. Inc. now owns 30,269 shares of the biopharmaceutical company’s stock worth $803,000 after acquiring an additional 4,515 shares during the period. ORG Partners LLC raised its stake in Pfizer by 6.2% during the fourth quarter. ORG Partners LLC now owns 50,879 shares of the biopharmaceutical company’s stock worth $1,351,000 after acquiring an additional 2,967 shares during the period. Finally, First International Bank & Trust acquired a new stake in Pfizer during the fourth quarter worth about $240,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Insider Buying and Selling

In other news, Director Scott Gottlieb acquired 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average price of $28.24 per share, with a total value of $28,240.00. Following the purchase, the director now owns 10,000 shares of the company’s stock, valued at approximately $282,400. This trade represents a 11.11 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.06% of the stock is currently owned by insiders.

Pfizer Trading Down 0.5 %

Pfizer stock opened at $26.73 on Friday. The firm has a 50 day simple moving average of $26.18 and a 200-day simple moving average of $28.04. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock has a market capitalization of $151.48 billion, a PE ratio of 36.12, a price-to-earnings-growth ratio of 0.63 and a beta of 0.64. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same period last year, the firm posted ($0.17) earnings per share. As a group, equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.43%. This is a boost from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is presently 232.43%.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on PFE shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research note on Wednesday, October 23rd. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Guggenheim dropped their price target on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Sanford C. Bernstein assumed coverage on shares of Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price target on the stock. Finally, StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Pfizer currently has an average rating of “Moderate Buy” and an average price target of $32.00.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.